Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples

Clinical Chemistry

Volumn 52, Issue 4, 2006, Pages 643-649

  Dean, Caroline J ^a   Bockmann, Michelle R ^a   Hopwoood, John J ^a,b   Brooks, Doug A ^a,b   Meikle, Peter J ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ANTIBODY; HYMECROMONE SULFATE; IDURONATE 2 SULFATASE; IMMOBILIZED ANTIBODY; LANTHANIDE;

ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DESICCATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISSOCIATION; DISSOCIATION ENHANCED LANTHANIDE FLUORESCENCE IMMUNOASSAY; DRIED BLOOD SPOT; EARLY DIAGNOSIS; ENZYME ACTIVITY; ENZYME IMMOBILIZATION; HUMAN; HUMAN TISSUE; HUNTER SYNDROME; IMMUNOASSAY; INFANT; PLASMA; PROTEIN BLOOD LEVEL; SCREENING TEST;

ADOLESCENT; ADULT; ANIMALS; BLOOD SPECIMEN COLLECTION; CALIBRATION; CHILD; CHILD, PRESCHOOL; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME TESTS; FLUOROMETRY; HUMANS; HYMECROMONE; IDURONATE SULFATASE; IMMUNOASSAY; INDICATORS AND REAGENTS; INFANT; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS II; PLASMA; RECOMBINANT PROTEINS;

EID: 33645458448     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.061838     Document Type: Article

References (35)

1. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic bases of inherited diseases, 8th ed. New York: McGraw-Hill, 2001:3421-52.
2. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003;21:577-81.
3. Villani GR, Balzano N, Grosso M, Salvatore F, Izzo P, Di Natale P. Mucopolysaccharidosis type II: identification of six novel mutations in Italian patients. Hum Mutat 1997;10:71-5.
4. Froissart R, Moreira da Silva I, Guffon N, Bozon D, Maire I. Mucopolysaccharidosis type II-genotype/phenotype aspects. Acta Paediatr Suppl 2002;91:82-7.
5. Parkinson EJ, Muller V, Hopwood JJ, Brooks DA. Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients. Mol Genet Metab 2004;81:58-64.
6. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 1999;22:638-48.
7. Wenstrup RJ, Bailey L, Grabowski GA, Moskovitz J, Oestreich AE, Wu W, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 2004;104:1253-7.
8. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74.
9. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J Pediatr 2004;144:581-8.
10. Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005;115: e681-9.
11. Muenzer J, Lamsa JC, Garcia A, Dacosta J, Garcia J, Treco DA. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl 2002;91:98-9.
12. Fuller M, Brooks DA, Evangelista M, Hein LK, Hopwood JJ, Meikle PJ. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 2005;84:18-24.
13. Hein LK, Meikle PJ, Dean CJ, Bockmann MR, Auclair D, Hopwood JJ, et al. Development of an assay for the detection of mucopolysaccharidosis type VI patients using dried blood-spots. Clin Chim Acta 2005;353:67-74.
14. Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ. Immunoquantification of α-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chem 2004;50:1979-85.
15. Umapathysivam K, Hopwood JJ, Meikle PJ. Determination of acid α-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem 2001;47:1378-83.
16. Keulemans JL, Sinigerska I, Garritsen VH, Huijmans JG, Voznyi YV, van Diggelen OP, et al. Prenatal diagnosis of the Hunter syndrome and the introduction of a new fluorimetric enzyme assay. Prenat Diagn 2002;22:1016-21.
17. Bielicki J, Freeman C, Clements PR, Hopwood JJ. Human liver iduronate-2-sulphatase. Purification, characterization, and catalytic properties. Biochem J 1990;271:75-86.
18. Voznyi YV, Keulemans JL, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis 2001;24:675-80.
19. Chamoles NA, Blanco MB, Gaggioli D, Casentini C. Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper. Clin Chem 2001;47:2098-102.
20. Bielicki J, Hopwood JJ, Wilson PJ, Anson DS. Recombinant human iduronate-2-sulphatase: correction of mucopolysaccharidosis-type II fibroblasts and characterization of the purified enzyme. Biochem J 1993;289(Pt 1):241-6.
21. Meikle PJ, Brooks DA, Ravenscroft EM, Yan M, Williams RE, Jaunzems AE, et al. Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem 1997;43:1325-35.
22. Anson DS, Taylor JA, Bielicki J, Harper GS, Peters C, Gibson GJ, et al. Correction of human mucopolysaccharidosis type-VI fibroblasts with recombinant N-acetylgalactosamine-4-sulphatase. Biochem J 1992;284(Pt 3):789-94.
23. Hopwood JJ. α-L-Iduronidase, β-D-glucuronidase, and 2-sulfo-L-iduronate 2-sulfatase: preparation and characterization of radioactive substrates from heparin. Carbohydr Res 1979;69:203-16.
24. Meikle PJ, Fietz MJ, Hopwood JJ. Diagnosis of lysosomal storage disorders: current techniques and future directions. Expert Rev Mol Diagn 2004;4:677-91.
25. Villani GR, Daniele A, Balzano N, Di Natale P. Expression of five iduronate-2-sulfatase site-directed mutations. Biochim Biophys Acta 2000;1501:71-80.
26. Bonuccelli G, Di Natale P, Corsolini F, Villani G, Regis S, Filocamo M. The effect of four mutations on the expression of iduronate-2-sulfatase in mucopolysaccharidosis type II. Biochim Biophys Acta 2001;1537:233-8.
27. Hopwood JJ, Ballabio A. Multiple sulfatase deficiency and the nature of the sulfatase family. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic bases of inherited diseases, 8th ed. New York: McGraw-Hill, 2001:3725-32.
28. Hanson SR, Best MD, Wong CH. Sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed Engl 2004;43:5736-63.
29. Butler JE. Solid supports in enzyme-linked immunosorbent assay and other solid-phase immunoassays. Methods 2000;22:4-23.
30. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
31. Hadd AG, Brown JT, Andruss BF, Ye F, WalkerPeach CR. Adoption of array technologies into the clinical laboratory. Expert Rev Mol Diagn 2005;5:409-20.
32. Karageorgos LE, Isaac EL, Brooks DA, Ravenscroft EM, Davey R, Hopwood JJ, et al. Lysosomal biogenesis in lysosomal storage disorders. Exp Cell Res 1997;234:85-97.
33. Hua CT, Hopwood JJ, Carlsson SR, Harris RJ, Meikle PJ. Evaluation of the lysosome-associated membrane protein LAMP-2 as a marker for lysosomal storage disorders. Clin Chem 1998;44:2094-102.
34. Chang MH, Bindloss CA, Grabowski GA, Qi X, Winchester B, Hopwood JJ, et al. Saposins A; B, C, and D in plasma of patients with lysosomal storage disorders. Clin Chem 2000;46:167-74.
35. Meikle PJ, Dean CJ, Grasby D, Bockmann MR, Whittle AM, Lang DL, et al. Newborn screening for lysosomal storage disorders: . evaluation of protein profiling [Abstract]. J Inherit Metab Dis 2005;28(Suppl 1):14.